Triazine Derivatives Modulate Trk Receptors for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases characterized by impaired neurotrophin signaling, such as Alzheimer's disease, lack effective small molecule modulators that can selectively target TrkA and TrkB receptors with improved potency and selectivity, and existing neurotrophins like BDNF face challenges in crossing the blood-brain barrier and have limited pharmacokinetic properties.
Innovation Solution
Development of novel 1,3,5-triazine compounds that act as potent modulators of Trk receptor signaling, specifically designed to stimulate or modulate TrkA and TrkB receptors, potentially offering improved metabolic properties for pharmaceutical development and enhanced efficacy in treating neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing neurotrophins like BDNF are used to treat diseases with impaired neurotrophin signaling, then therapeutic effect is achieved, but pharmacokinetic properties are limited and blood-brain barrier crossing is difficult
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that can cross the blood-brain barrier and activate Trk receptors, bypassing the limitation of large neurotrophin molecules that cannot efficiently cross the barrier. These small molecules serve as mediators between the administration site and the target receptors in the brain.
Solution Approach 2:
The patent creates small molecule copies or mimics of the biological activity of neurotrophins, capturing the essential receptor-activating function in a chemically simplified form that has improved pharmacokinetic properties while maintaining therapeutic efficacy.
2Measurement precision
If small molecule modulators are developed to target Trk receptors, then receptor selectivity and potency are improved, but development complexity increases
Solution Approach 1:
The patent employs structure-activity relationship analysis to optimize specific molecular features of the small molecules, making local modifications to enhance Trk receptor selectivity and potency while maintaining reasonable development complexity through focused molecular design.
3Reliability
If potent Trk receptor modulators are used to treat neurodegenerative diseases, then cognitive function and neuroprotection are improved, but selectivity between TrkA and TrkB receptors must be maintained
Solution Approach 1:
The patent systematically varies molecular parameters such as substituent groups, molecular weight, and structural features of the small molecules to optimize the balance between potency and selectivity for specific Trk receptor subtypes, enabling differentiated therapeutic effects.
Data Source
AI summary
There is provided a compound of formula I, (I) wherein R1 and R2 are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.